Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes.Subjects, materials and methods This was a single-centre, randomised, double-blind study in drug-naive patients with type 2 diabetes. Patients received vildagliptin (50 mg twice daily, n=15) or placebo (n=16) for 4 weeks. Triglyceride, cholesterol, lipoprotein, glucose, insulin, glucagon and glucagon-like peptide-1 (GLP-1) responses to a fat-rich mixed meal were determined for 8 h postprandially before and after 4 weeks of treatment.Results Relative to placebo, 4 weeks of treatment with vildagliptin decreased the AUC(0-8h) for total trigyceride by 22+/-11% (p=0.037), the incremental AUC(0-8h) (IAUC(0-8h)) for total triglyceride by 85+/-47% (p=0.065), the AUC(0-8h) for chylomicron triglyceride by 65+/-19% (p=0.001) and the IAUC(0-8h) for chylomicron triglyceride by 91+/-28% (p=0.002). This was associated with a decrease in chylomicron apolipoprotein B-48 (AUC(0-8h), -1.0+/-0.5 mg l(-1) h, p=0.037) and chylomicron cholesterol (AUC(0-8h), -0.14+/-0.07 mmol l(-1) h, p=0.046). Consistent with previous studies, 4 weeks of treatment with vildagliptin also increased intact GLP-1, suppressed inappropriate glucagon secretion, decreased fasting and postprandial glucose, and decreased HbA(1c) from a baseline of 6.7% (change, -0.4+/-0.1%, p<0.001), all relative to placebo.Conclusions/interpretation Treatment with vildagliptin for 4 weeks improves postprandial plasma triglyceride and apolipoprotein B-48-containing triglyceride-rich lipoprotein particle metabolism after a fat-rich meal. The mechanisms underlying the effects of this dipeptidyl peptidase IV inhibitor on postprandial lipid metabolism remain to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, a four-week treatment with DPP-4 inhibitor vildagliptin was also found to induce reductions in the postprandial TG and apolipoprotein B-48 containing TG-rich lipoprotein particle metabolism after a fat meal [177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationType 2 Diabetes as a “Coronary Heart Disease Equivalent”
Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2901 · Cited by 452
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationMaggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 3×
“This situation contrasts with the recent finding in healthy volunteers that exogenous GLP1 infusion (which increased plasma levels >10-fold) eliminated the postprandial increase in TGs [27].”
ResultInfluential
Cited by
Items 101–200 of 336
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
“Lipoprotein fractions [chylomicrons (Svedberg flotation rate (Sf) > 400), large VLDL1 particles (Sf 60–400) and smaller VLDL2 particles (Sf 20–60)] from all serum samples drawn during the postprandial apoC-III kinetic study were separated by density gradient ultracentrifugation.(41)”
BackgroundSelf-citationEleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“(2006) [107] investigated in a randomized, double-blind, placebo-controlled study the effect of vildagliptin on postprandial lipoprotein particles in patients with type 2 DM.”
BackgroundClinical evidence and mechanistic basis for vildagliptin's action when added to metformin
Åhrén, B., Foley, J. E., & Bosi, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01321.x · Cited by 64
Self-citationTani, S., Nagao, K., & Hirayama, A. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0043-2 · Cited by 62
Mulvihill, E. E. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.023 · Cited by 62
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 63
Rosenstock, J., Niggli, M., & Maldonado‐Lutomirsky, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01021.x · Cited by 57
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
Henness, S., & Keam, S. J. (2006) · Drugs · doi:10.2165/00003495-200666150-00007 · Cited by 72
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Turcot, V., Bouchard, L., Faucher, G., Tchernof, A., Deshaies, Y., Përusse, L., Bélisle, A., Marceau, S., Biron, S., Lescelleur, O., et al. (2010) · Obesity · doi:10.1038/oby.2010.198 · Cited by 56
The protective role of DPP4 inhibitors in atherosclerosis
Liu, H., Guo, L., Xing, J., Li, P., Sang, H., Hu, X., Du, Y., Zhao, L., Song, R., & Gu, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173037 · Cited by 60
Absence of Acute Inhibitory Effect of Insulin on Chylomicron Production in Type 2 Diabetes
Nogueira, J.-P., Maraninchi, M., Béliard, S., Padilla, N., Duvillard, L., Mancini, J., Nicolay, A., Xiao, C., Vialettes, B., Lewis, G. F., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.242073 · Cited by 52
Intestinal lipid absorption and transport in type 2 diabetes
Vergès, B. L. (2022) · Diabetologia · doi:10.1007/s00125-022-05765-8 · Cited by 64
Fukuda-Tsuru, S., Anabuki, J., Abe, Y., Yoshida, K., & Ishii, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.024 · Cited by 53
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors
Åhrén, B. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0056-9 · Cited by 54
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
Duggan, E. W., & Chen, Y. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1277-4 · Cited by 51
Sunkara, G., Sabo, R., Wang, Y., He, Y., Campestrini, J., Rosenberg, M. A., Howard, D., & Dole, W. P. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007304313 · Cited by 47
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P., Bailey, C., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Atherosclerosis, diabetes and lipoproteins
TOMKIN, G. H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.45 · Cited by 50
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Avogaro, A., Kreutzenberg, S., & Fadini, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 45
Shigiyama, F., Kumashiro, N., Miyagi, M., Iga, R., Kobayashi, Y., Kanda, E., Uchino, H., & Hirose, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12587 · Cited by 45
Gibbs, J. P., Fredrickson, J. O., Barbee, T., Correa, I., Smith, B. P., Lin, S., & Gibbs, M. A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011420153 · Cited by 44
von Eynatten, M., Gong, Y., Emser, A., & Woerle, H. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-60 · Cited by 44
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14328 · Cited by 40
“Chylomicrons, large VLDL1 particles and smaller VLDL2 particles were isolated by density gradient ultracentrifugation as described.(21) TRLcholesterol (TRL-C) (i.”
MethodSelf-citationIncretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
Farr, S., & Adeli, K. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d68f0 · Cited by 40
Rhee, E., Lee, W., Yoon, K., Yoo, S. J., Lee, I. K., Baik, S. H., Kim, Y. K., Lee, M. ‐., Park, K. S., Park, J. Y., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01303.x · Cited by 41
Burgmaier, M., Heinrich, C., & Marx, N. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03746.x · Cited by 40
Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway
Aldakinah, A.-A. A., Al‐Shorbagy, M. Y., Abdallah, D. M., & El-Abhar, H. S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12713 · Cited by 45
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 38
Vildagliptin in clinical practice: a review of literature
Banerjee, M., Younis, N., & Soran, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903302265 · Cited by 38
Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies
Yuan, Y., Ran, N., Xiong, L., Wang, G., Guan, X., Wang, Z., Guo, Y., Pang, Z., Fang, K., Lu, J., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/1943497 · Cited by 43
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 38
Bayrami, G., Karimi, P., Aghahoseini, F., Feyzizadeh, S., & Badalzadeh, R. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417729881 · Cited by 33
Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
Shigematsu, E. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1889w · Cited by 38
Davidson, M. H. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.033 · Cited by 35
Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D’Angelo, A., & Maffioli, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.008 · Cited by 34
The regulatory role of DPP4 in atherosclerotic disease
Duan, L., Rao, X., Xia, C. Q., Rajagopalan, S., & Zhong, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0558-y · Cited by 39
The scientific evidence: vildagliptin and the benefits of islet enhancement
Mathieu, C. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01033.x · Cited by 33
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Koška, J., Sands, M. A., Burciu, C., & Reaven, P. D. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114562411 · Cited by 35
Parlevliet, E. T., der Elst, J. P. S.-V., Corssmit, E. P. M., Picha, K. M., O’Neil, K. T., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., & Pijl, H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144154 · Cited by 37
Tremblay, A. J., Lamarche, B., Kelly, I., Charest, A., Lépine, M. ‐., Droit, A., & Couture, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12359 · Cited by 31
Jamaluddin, J. L., Huri, H. Z., & Vethakkan, S. R. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0010 · Cited by 33
Taskinen, M.-R., Björnson, E., Andersson, L., Kahri, J., Porthan, K., Matikainen, N., Söderlund, S., Pietiläinen, K., Hakkarainen, A., Lundbom, N., et al. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.12.003 · Cited by 30
Self-citationTaskinen, M.-R., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N., Fermanelli, V., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 30
Self-citationTaskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 31
Self-citationElBatsh, M. M., El‐Batch, M., Shafik, N. M., & Younos, I. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.033 · Cited by 31
Bayrami, G., Alihemmati, A., Karimi, P., Javadi, A., Keyhanmanesh, ., Mohammadi, M., Heydarabad, M. Z., & Badalzadeh, R. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.037 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Fuchs, S., Yusta, B., Baggio, L. L., Varin, E. M., Matthews, D., & Drucker, D. J. (2020) · JCI Insight · doi:10.1172/jci.insight.136907 · Cited by 29
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Cao, F., Wu, K., Zhu, Y., & Bao, Z.-W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731273 · Cited by 36
Campbell, R. K., & White, J. R. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708317870 · Cited by 34
Kakuda, H., Kobayashi, J., Kakuda, M., Yamakawa, J.-I., & Takekoshi, N. (2014) · Endocrine · doi:10.1007/s12020-014-0376-x · Cited by 30
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes
Chaudhuri, A., & Dandona, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01423.x · Cited by 28
Matikainen, N., & Taskinen, M. (2012) · Diabetic Medicine · doi:10.1111/dme.12094 · Cited by 27
Self-citationMasuda, D., Kobayashi, T., Sairyou, M., Hanada, H., Ohama, T., Koseki, M., Nishida, M., Maeda, N., Kihara, S., Minami, T., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.41343 · Cited by 28
Terawaki, Y., Nomiyama, T., Takahashi, H., Tsutsumi, Y., Murase, K., Nagaishi, R., Tanabe, M., Kudo, T., Kobayashi, K., Yasuno, T., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0043-2 · Cited by 26
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
Yang, G., Li, Y.-Z., Cui, L., Jiang, H., Li, X., Jin, C., Jin, D., Zhao, G., Jin, J., Sun, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163027 · Cited by 27
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1705 · Cited by 25
Enteroendocrine cells and lipid absorption
Mellitzer, G., & Gradwohl, G. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834622a2 · Cited by 32
Wu, J., Qian, P., Han, Y., Xu, C., Mao, X., Zhan, P., Wei, J., & Dong, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01260-3 · Cited by 27
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice
Marques, A. P., Cunha‐Santos, J., Leal, H., Sousa-Ferreira, L., de Almeida, L. P., Cavadas, C., & Rosmaninho‐Salgado, J. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.11.012 · Cited by 28
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
Voukali, M., Kastrinelli, I., Stragalinou, S., Tasiopoulou, D., Paraskevopoulou, P., Katsilambros, N., Kokkinos, A., Tentolouris, N., & Ioannidis, I. (2014) · Journal of Diabetes Research · doi:10.1155/2014/304032 · Cited by 24
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 26
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 25
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Dejager, S., Schweizer, A., & Foley, J. E. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s31758 · Cited by 21
Self-citationMinor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
Matikainen, N., Björnson, E., Söderlund, S., Borén, C., Eliasson, B., Pietiläinen, K. H., Bogl, L. H., Hakkarainen, A., Lundbom, N. M. I., Rivellese, A. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145890 · Cited by 23
Self-citationMaksoud, H. A. A., Zaid, O. A. R. A., Elharrif, M. G., Omnia, M. A., & Alaa, E. A. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.07.016 · Cited by 28
Small dense low-density lipoprotein-lowering agents
Alizadeh‐Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B., & Khosravi, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0426 · Cited by 28
Onoyama, T., Koda, M., Okamoto, T., Kishina, M., Matono, T., Sugihara, T., & Murawaki, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4329 · Cited by 24
Green, J. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6270 · Cited by 22
Yousefzadeh, P., & Wang, X. (2013) · Journal of Diabetes Research · doi:10.1155/2013/459821 · Cited by 21
Fang, Q., Wang, J., Zhang, Y., Wang, L., Li, W., Han, J., Huang, W., Liang, G., & Wang, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.026 · Cited by 21
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 23
Devanathan, S., Nemanich, S. T., Kovács, A. D., Fettig, N. M., Gropler, R. J., & Shoghi, K. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078477 · Cited by 20
Wang, X.-M., Yang, Y., & Wu, Y. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6459-8 · Cited by 25
Heruc, G. A., Horowitz, M., Deacon, C. F., Feinle‐Bisset, C., Rayner, C. K., Luscombe‐Marsh, N. D., & Little, T. J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2014 · Cited by 21
Warnakula, S., Hsieh, J., Adeli, K., Hussain, M. M., Tso, P., & Proctor, S. D. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.020 · Cited by 21
Turcot, V., Tchernof, A., Deshaies, Y., Përusse, L., Bélisle, A., Marceau, P., Hould, F., Lebel, S., & Vohl, M. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-4 · Cited by 20
Potential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies
Zhong, J., Kankanala, S., & Rajagopalan, S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000340 · Cited by 22
Obesity and type 2 diabetes: can we find a compromised treatment solution?
Galstyan, G. R., Shestakova, E. A., & Sklyanik, I. A. (2017) · Diabetes Mellitus · doi:10.14341/dm8726 · Cited by 26
Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010085 · Cited by 22
Pepa, G. D., Patrício, B. G., Carli, F., Sabatini, S., Astiarraga, B., Ferrannini, E., Camastra, S., & Gastaldelli, A. (2024) · Diabetes · doi:10.2337/db23-0972 · Cited by 20
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Madsbad, S. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.11.003 · Cited by 19
Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes
Wu, J. Q., Chen, Y., Shi, X., & Gu, W. (2009) · 南京医科大学学报:英文版 · doi:10.1016/s1007-4376(09)60061-7 · Cited by 17
Ahn, C. H., Han, K. A., Yu, J. M., Nam, J. Y., Ahn, K. J., Oh, T. K., Lee, H. W., Lee, D. H., Kim, J., Chung, C. H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12866 · Cited by 16
Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors in Patients With Diabetes Mellitus
Moore, K. B., & Saudek, C. D. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180ed42dc · Cited by 15
GLP1, an Important Regulator of Intestinal Lipid Metabolism
Dallinga‐Thie, G. M., & Nieuwdorp, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305479 · Cited by 17
Alogliptin benzoate for the treatment of type 2 diabetes
Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 16
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
Prato, S. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01439.x · Cited by 16
Metadata
- Authors
- Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R.
- Affiliations
- Helsinki University Hospital (FI)
- Novartis (Switzerland) (CH)
- Corresponding author
- Taskinen, M.-R.
- Venue
- Diabetologia
- Published
- 2006-07-01
- Volume
- 49
- Issue
- 9
- Pages
- 2049-2057
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2152978153
- Cited by
- 336
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 2 · 2022: 8 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 15 · 2016: 24 · 2015: 23 · 2014: 34 · 2013: 38 · 2012: 29
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- DPP-4 inhibitors, type 2 diabetes, postprandial lipemia, triglyceride-rich lipoproteins, chylomicrons, apolipoprotein B-48, glucagon-like peptide-1, glucagon secretion, postprandial lipoprotein metabolism
- MeSH terms
- Vildagliptin, Adamantane, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Insulin, Intestinal Mucosa, Intestines, Lipids, Lipoproteins, Male, Middle Aged, Nitriles, Pyrrolidines, Time Factors, Triglycerides, Treatment Outcome, Postprandial Period, Glucagon-Like Peptide 1, Apolipoprotein B-48, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.